Economics & Value

Value Frameworks Unreliable in Assessing Novel Hematologic Therapies

Chase Doyle

February 2017, Vol 8, No 1 - Value-Based Care

San Diego, CA—The American Society of Clinical Oncology (ASCO) and the European Society for Medical Oncology (ESMO) developed frameworks to determine the relative value of novel therapeutic agents. These value frameworks, however, may need to be modified to assess treatments for hematologic malignancies, suggested Matthew C. Cheung, MD, SM, FRCPC, Clinical Hematologist, Odette Cancer Centre, Toronto, Ontario, Canada, at the 2016 American Society of Hematology meeting. [ Read More ]

ASCO Value Framework Ill-Equipped to Assess Value of Therapies in Chronic Lymphocytic Leukemia

Chase Doyle

February 2017, Vol 8, No 1 - Value-Based Care

San Diego, CA—A study examining the feasibility and applicability of the American Society of Clinical Oncology (ASCO) Value Framework in chronic lymphocytic leukemia (CLL) suggests that the tool, although useful in assessing a small percentage of drug regimens, may need to be amended to be useful in CLL, reported Erlene K. Seymour, MD, Assistant Professor, Department of Oncology, Karmanos Cancer Institute, Wayne State University, Detroit, MI, at the 2016 American Society of Hematology meeting. [ Read More ]

New Value Model Incorporates Long-Term Adverse Effects of Cancer Drugs

Chase Doyle

February 2017, Vol 8, No 1 - Value-Based Care

A new economic model suggests that overall survival and drug toxicity profiles are insufficient for assessing the value of a drug. According to a study that incorporated late adverse events in advanced Hodgkin lymphoma, a more comprehensive benefit-to-risk ratio of a drug requires an understanding of its long-term health implications, said Ohad Oren, MD, Pennsylvania Hospital, University of Pennsylvania, Philadelphia, at the 2016 American Society of Hematology meeting. [ Read More ]

Patients with Cancer Eager to Discuss Costs of Care with Their Oncologists

Laura Morgan

September 2015, Vol 6, No 8 - Economics of Cancer Care

Gone are the days when patients with cancer were, for the most part, protected from healthcare costs by their medical insurance. According to a recent study sponsored by the National Comprehensive Cancer Network and conducted by Ronan J. Kelly, MD, MBA, MBBCh, Assistant Professor of Oncology, Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, Baltimore, and colleagues, with high deductibles, escalating copayments, and cost-sharing requirements becoming the status quo, patients with cancer are now, more than ever, feeling the effects of financial toxicity, particularly young patients who are especially susceptible to filing for medical bankruptcy (Kelly RJ, et al. J Oncol Pract. 2015;11:308-312). [ Read More ]

Assessing the Cost-Effectiveness of Necitumumab in Squamous-Cell Lung Cancer

Dana Taylor

August 2015, Vol 6, No 7 - Economics of Cancer Care

Chicago, IL—An economic analysis presented by Daniel Goldstein, MD, of Emory University, Atlanta, GA, at the 2015 American Society of Clinical Oncology meeting, was conducted to see at what price will necitum­umab (which is currently being reviewed by the FDA for use in metastatic squamous-cell lung cancer) be cost-­effective. According to this analysis, necitumumab will have to be priced at less than $1300 per cycle to be cost-­effective based on the accepted willing­ness-to-­pay threshold of $150,000. [ Read More ]